Drugs / Hematopoietic cell transplantation
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03591302 | Feb 2024 → Oct 2028 expected | — | Stephan Busque | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00319657 | Jul 2004 → Jul 2026 overdue | — | Stanford University | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hematopoietic cell transplantation | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03591302 ↗ |
| Modality | Cell therapy | “Transplantation of hematopoietic stem cells from the living donor.” NCT00319657 ↗ |